Search

EHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation

To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).

Read more

EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Syndromes

The second scientific meeting on EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Disorders and Leukemia Predisposing Genes was held on October 10-12, 2019 in Prague, Czech Republic.

Read more

1st joint EHA – Balkan Hematology Day, a meeting of true regional commitment

1st joint EHA – Balkan Hematology Day

Friday, October 11, 2019 | Pravets, Bulgaria

Meeting Chairs:

Prof Gert Ossenkoppele, Chair EHA Education Committee
Prof Gianluca Gaidano, Chair EHA Global Outreach Program Unit
Prof Margarita Guenova, Representative Balkan Societies

On Friday, October 11th the European Hematology Association (EHA)…

Read more

EHA-AHA Hematology Tutorial On Lymphoid Malignancies Attracts International Audience

EHA-AHA Hematology Tutorial on Lymphoid Malignancies

October 18-20, 2019 | Yerevan, Armenia

Meeting chairs:
Prof G Gaidano (European Hematology Association)
Prof Y Hakobyan (Armenian Hematology Association)
Prof S Danielyan (Haematology center after Prof. R. H.

Read more

Meeting report | HOPE LA 2019 | Mendoza, Argentina

The first edition of the Highlights of Past EHA (HOPE) meeting in Latin America (LA) was held on October 4-5, 2019 in Mendoza, Argentina.

Read more

Mentoring peer-peer networks – a recipe for success

Isabel Peset1 & Alba Maiques-Diaz2

1 Senior Scientist, Microscopy, Medicines Discovery Catapult, Manchester, UK;
2 Postdoctoral scientist, Biomedical Epigenomics group, IDIBAPS, Barcelona, Spain; YoungEHA committee member.

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

COST Action ‘EuNet-INNOCHRON’

The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.

Read more

Open Access: the ‘Plan S’

 

Research and academic groundwork funded with public means should be free and open to everyone. That is the principle behind Open Access that was formulated in 2003 in the Berlin Declaration.

Read more